Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) was the target of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 702,300 shares, an increase of 84.1% from the November 15th total of 381,500 shares. Based on an average trading volume of 403,300 shares, the short-interest ratio is currently 1.7 days.
Institutional Investors Weigh In On Silence Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new position in Silence Therapeutics during the 3rd quarter worth $56,000. Quarry LP bought a new position in shares of Silence Therapeutics in the second quarter worth $114,000. Verition Fund Management LLC acquired a new position in Silence Therapeutics in the third quarter valued at about $207,000. Custom Index Systems LLC acquired a new position in Silence Therapeutics in the second quarter valued at about $282,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Silence Therapeutics during the third quarter worth about $318,000. 98.73% of the stock is currently owned by institutional investors.
Silence Therapeutics Trading Up 2.3 %
NASDAQ SLN traded up $0.15 during trading on Thursday, reaching $6.60. The company's stock had a trading volume of 651,527 shares, compared to its average volume of 266,942. The firm has a 50 day moving average price of $14.19 and a 200 day moving average price of $17.32. Silence Therapeutics has a 12 month low of $5.81 and a 12 month high of $27.72. The firm has a market capitalization of $197.52 million, a price-to-earnings ratio of -4.11 and a beta of 1.05.
Analysts Set New Price Targets
Several equities analysts have commented on SLN shares. William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Chardan Capital restated a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday. Morgan Stanley restated an "overweight" rating and set a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Monday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $57.20.
Read Our Latest Stock Report on Silence Therapeutics
About Silence Therapeutics
(
Get Free Report)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Featured Stories
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
